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icute coronary syndromes (ACS) now account for approx-
mately 1.6 million hospitalizations as determined by pri-
ary and secondary discharge diagnoses (1). The majority
f these are without ST-segment elevation (STE), i.e.,
on–ST-segment elevation-acute coronary syndrome
nSTE-ACS). In this year’s report, we highlight scientific
apers that were published or presented between May 2005
nd April 2006 in 6 areas: pathogenesis, risk assessment,
ntithrombotic therapy, percutaneous coronary interven-
ion, lipids, and women and minorities.
ATHOGENESIS
here has been considerable progress in our understanding
f the pathogenesis of ACS (2). Sudden luminal thrombosis
hat is a consequence of either plaque rupture (most com-
on), plaque erosion (in approximately one-third), or a
alcified nodule (10%) is responsible for most cases of
CS (3). Recent research has focused on the detection of
vulnerable” plaques (Table 1). The ideal method to detect
uch plaques would permit rapid screening of the entire
oronary tree (4), because many ACS patients have multiple
ulnerable plaques, particularly if systemic inflammation is
resent (5).
ISK ASSESSMENT
he Thrombolysis In Myocardial Infarction (TIMI) risk
ndex (age2 heart rate/systolic blood pressure) is simple to
alculate and was initially developed for patients with STE
yocardial infarction (6). It has now also been validated in
atients with nSTE-ACS (7). The prognostic capabilities of
xisting nSTE-ACS risk scores can be improved by adding
nformation from the clinical history (e.g., depression [8],
rectile dysfunction [9]), electrocardiogram (ECG) (e.g.,
TE in aVR [10], quantitative ST-segment deviation [11]),
chocardiogram (e.g., left ventricular function and perfusion
12]), and serum markers (e.g., C-reactive protein [CRP]
13]), albeit at the cost of increasing complexity. Among
atients with an initial normal troponin concentration, the
resence of ST-segment depression, short delay (8 h) to
resentation, and absence of prior percutaneous coronary
From the TIMI Study Group, Division of Cardiovascular Medicine, Department
f Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston,t
assachusetts.
Manuscript received May 2, 2006; accepted May 9, 2006.ntervention (PCI) are the strongest predictors of an ele-
ated late troponin (14), while the presence of insulin-
ependent diabetes carries a 4-fold increase in the risk of
eath or reinfarction at 1 year (15).
iomarkers. The past year added new information re-
arding markers of necrosis, ventricular stress, inflamma-
ion, and metabolic status in patients with nSTE-ACS.
levated troponin is associated with yellow lipid-rich
laques and thrombus at angioscopy (16). When tropo-
in is detected, even among patients without critical
picardial stenoses, it is associated with higher rates of
eath and reinfarction (17). Prior studies demonstrated
he association of a single B-type natriuretic peptide
BNP) measured after presentation with an ACS with
hort-term and long-term risk of death and heart failure
18). More recently, changes in BNP over time predicted
ong-term outcomes, thus providing a tool that could be
sed to tailor therapy after ACS (19).
Numerous inflammatory biomarkers that may be useful
n predicting the risk of patients with nSTE-ACS have
een identified. These include cytokines (20) (e.g.,
nterleukin-6, monocyte chemoattractant protein-1),
cute phase reactants (21) (e.g., CRP, serum amyloid A),
arkers of endothelial cell activation and leukocyte
dhesion (21) (e.g., soluble intercellular adhesion
olecule-1, E-selectin), markers of oxidative stress (22)
e.g., myeloperoxidase, oxidized low-density lipoprotein
LDL], A2 phospholipases), angiogenic growth factors
22) (e.g., vascular endothelial and placental growth
actors), matrix metalloproteinases (MMP) (23) (e.g.,
MP-1, -2, -9; pregnancy-associated plasma protein A
PAPP-A]), and markers of platelet activation (23) (e.g.,
oluble CD-40 ligand, P-selectin). Three of the most
romising novel markers (PAPP-A [24], placental
rowth factor [PlGF] [25], secretory phospholipase A2
sPLA2] [26]) are independent predictors of death or
einfarction in patients with ACS (Table 2).
The overlap of metabolic derangement and cardiac bi-
markers is being actively investigated. Using the novel
pplication of metabolomics, changes in citric acid metab-
lites have been shown to be associated with acute myocar-
ial ischemia (27). In 2 independent cohorts, high blood
lucose during ACS was associated with a 1.7-fold increase
n mortality, and also was correlated with elevated levels of
roponin and BNP (28).
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ariability in antiplatelet response. The notion that pa-
ients exhibit a variable pharmacologic response to anti-
latelet therapy is now entering its 5th decade. However,
nterest in this area has intensified recently in light of the
reater ease of assessing pharmacodynamic effects of an
ncreasing number of available antiplatelet therapies, and
vidence that now correlates pharmacodynamic effect with
linical outcomes (29). Research on variable antiplatelet
harmacodynamic responses has been hampered by the lack
f a universally accepted definition, absence of a gold-
tandard methodology (30), multiple mechanisms of hypo-
esponse, and, until recently, an uncertain relationship with
linical outcomes (31). Patients prescribed low-dose
nteric-coated aspirin for secondary prevention who are
oung, overweight, or have had a prior myocardial infarction
re more likely to have an inadequate pharmacodynamic
esponse to aspirin (32). Some patients who are hypore-
ponsive to aspirin also may have a lower-than-expected
harmacologic effect after administration of clopidogrel
33), raising the possibility of a common mechanism.
ndeed, the glycoprotein IIIa single nucleotide platelet
ntigen polymorphism PLA2 (34) and the C807T polymor-
hism of the glycoprotein Ia gene (35) each have been
inked to variability in response to aspirin and clopidogrel.
vidence supports a relationship between an inadequate
harmacologic response to aspirin plus clopidogrel with
eriprocedural necrosis (36), subacute stent thrombosis
37), and clinical events through 6 months after PCI (Fig. 1)
38). Whether the same applies to glycoprotein IIb/IIIa
nhibitors (GPI) remains to be proven, and is further
able 1. Modalities to Detect Vulnerable Coronary Plaques
ntravascular catheter-based techniques
Ultrasound
Optimal coherence tomography
Near-infrared spectroscopy
Thermography
Palpography
Magnetic resonance imaging
Beta-radiation–sensitive catheters
oninvasive techniques
Multidetector row computerized tomographic angiography
Magnetic resonance imaging
Radionuclide imaging
dapted from J Am Coll Cardiol 2006;47(8)Suppl C.
able 2. Novel Inflammatory Markers That Independently Predi
Marker Ref. # Timing HR (95%
APP-A 24 6 months 2.3 (1.3–4
IGF 25 4 yrs* 3.0 (1.4–6
PLA2 26 6 months 3.1 (1.4–6
Among survivors free of myocardial infarction at 6 months.
CAD  coronary artery disease; CI  confidence interval; CRP  C-reactive protein;
lacental growth factor; sPLA2  secretory phospolipase A2.omplicated by a difference in antiplatelet effect achieved by
ach of the 3 GPIs (39).
ntiplatelet trials. New data regarding the timing, loading
ose, and duration of clopidogrel treatment were published
n the past year. In a subgroup analysis from the CURE
Clopidogrel in Unstable angina to prevent Recurrent
vents) trial, clopidogrel (compared with placebo) showed
onsistent treatment benefit over the 9-month follow-up
eriod regardless of the timing of PCI (40). Some of the
arly benefit of clopidogrel may be explained by its ability to
lock the rebound hypercoagulable state after heparin dis-
ontinuation in patients with ACS (41). Because a 300-mg
oading dose of clopidogrel appears to have little benefit
hen the treatment duration is 12 h before PCI (42),
igher doses have been investigated. Data from trials of
atients without preceding nSTE-ACS who underwent
CI demonstrated higher levels of active metabolite and
latelet inhibition with a 600-mg load (but no further
ncremental benefit with 900 mg) (43), and less frequent
eriprocedural myocardial infarction (44).
Three important questions with regard to the role of GPI
herapy—efficacy on a background of 600-mg clopidogrel,
pstream versus downstream use, and comparison to regi-
ens containing bivalirudin—were explored in clinical trials
uring the past year. In the ISAR-REACT 2 (Abciximab in
atients with Acute Coronary Syndromes Undergoing Per-
utaneous Coronary Intervention After Clopidogrel Pre-
reatment) trial, abciximab reduced the composite of death,
yocardial infarction (MI), or urgent target vessel revascu-
arization within 30 days compared with placebo by 25% (p
0.03) among 2,022 patients with nSTE-ACS, all of
hom received clopidogrel 600 mg at least 2 h before PCI
45). However, the benefit of abciximab was observed only
n patients with nSTE-MI (Fig. 2). The EVEREST
Randomized Comparison of Upstream Tirofiban versus
ownstream High Bolus Dose Tirofiban or Abciximab on
issue-Level Perfusion and Troponin Release in High-Risk
cute Coronary Syndromes Treated with Percutaneous
oronary Interventions) trial of 93 patients with high-risk
STE-ACS compared upstream tirofiban to downstream
igh bolus-dose tirofiban and downstream abciximab 10
in before PCI. Upstream tirofiban improved TIMI myo-
ardial perfusion before and after PCI, achieved a higher
yocardial contrast echocardiographic score, and resulted in
ath or Reinfarction
Additional Variables Included in the Multivariable Model
Age, gender, diabetes, hypercholesterolemia, hypertension,
prior CAD, ST-segment depression, troponin T, CRP
Age, gender, diabetes, ST-segment depression, troponin T,
CRP, CD-40 ligand
Age, creatinine, Killip class, prior coronary artery bypass
graftingct De
CI)
.2)
.7)
.9)HR  hazard ratio; PAPP-A  pregnancy-associated plasma protein A; PIGF 
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Year in Review in nSTE-ACS July 18, 2006:386–95ower rates of post-procedure troponin elevation (46). Pre-
iminary results from the open-label ACUITY (Acute
atheterization and Urgent Intervention Triage strategY)
iming trial in 9,207 patients randomized to upstream GPI
dministered on average 6 h before PCI compared with
ownstream use begun in the catheterization laboratory
emonstrated that a downstream strategy was non-inferior
or a quaternary net clinical benefit end point (death,
yocardial infarction, unplanned revascularization for isch-
mia, major bleeding), but did not satisfy the non-inferiority
riterion for the triple ischemic end point (47). A cost-
ffective analysis using data from the TACTICS–TIMI-18
Prognostic Implications of Elevated Troponin in Patients
ith Suspected Acute Coronary Syndrome but no Critical
picardial Coronary Disease–Thrombolysis In Myocardial
nfarction-18) trial concluded that upstream use of tirofiban
as superior to selective use, and was cost-effective in
oderate- to high-risk patients (48). Taken together, these
tudies suggest that upstream GPI therapy may be more
ffective than downstream use in moderate- to high-risk
atients managed with an invasive strategy in whom imme-
iate catheterization is not planned. The EARLY ACS
Early Glycoprotein IIb/IIIa Inhibition in Non–ST-
egment Elevation Acute Coronary Syndrome) study (49)
igure 1. Less measurable antithrombotic effect of clopidogrel correlates w
latelet reactivity (defined as the average of platelet aggregation over 3 tim
igher in those patients who developed a myocardial infarction (creatine k
ith an elevation of CK-MB to 1 to 3 ULN, and lowest in patients wit
38), the post-treatment clot strength (MA) measured by a thromboelastog
ith that in patients without an ischemic event. In the CREST study (37), 
eactivity ratio than patients without SAT. The PGY12 reactivity ratio is in
y clopidogrel.s an ongoing randomized, double-blind, clinical trial com- Iaring upstream double-bolus eptifibatide to downstream
elective use in high-risk patients with nSTE-ACS who are
ot undergoing PCI in the first 12 h and should help shed
urther light on this issue.
Three new antiplatelet drugs are in phase III clinical
rials, including a potent, fast-acting thienopyridine (pra-
ugrel [50]), a reversible oral PGY12 inhibitor (AZD6140, a
yclopentyltriazolopyridimidine [51]), and a potent, short-
cting intravenous PGY12 inhibitor (cangrelor [52]). In
atients with nSTE-ACS, preliminary data from the DIS-
ERSE 2 (Safety, Tolerability and Preliminary Efficacy of
ZD6140, the First Oral Reversible ADP Receptor An-
agonist, Compared with Clopidogrel in Patients with
on–ST-Segment Elevation Acute Coronary Syndrome)
rial comparing AZD6140 with placebo demonstrated that
ZD6140 180 mg twice daily achieved greater and more
onsistent platelet inhibition and showed favorable effects
n clinical outcomes, without an increase in major bleeding
53).
nticoagulant trials. Several studies investigated newer
rugs that target more distal factors in the coagulation
ascade (e.g., bivalirudin [54]), or more proximal factors
e.g., enoxaparin, fondaparinux) than does the standard
nticoagulant, unfractionated heparin [UFH]. In the ACU-
rse clinical outcome. In the CLEAR PLATELETS study (36), the mean
ints in the first 24 h after percutaneous coronary intervention [PCI]) was
[CK]-MB 3 upper limits of normal [ULN]), intermediate in patients
ormal CK-MB after PCI. In the PREPARE POST-STENTING study
TEG) was greater in patients with ischemic events at 6 months compared
ts who experienced subacute stent thrombosis (SAT) had a higher PGY12
ly correlated with the degree of adenosine diphosphate-induced inhibitionith wo
e po
inase
h a n
raph (
patienTY trial, 13,819 patients with moderate- to high-risk
n
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July 18, 2006:386–95 Year in Review in nSTE-ACSSTE-ACS were randomized to 1 of 3 arms: heparin 
PI (standard), bivalirudin  GPI (combination), or biva-
irudin alone (monotherapy) (55). The primary end point
as net clinical benefit (see the preceding text). Combina-
ion therapy was non-inferior to the standard (neither arm
as superior), while monotherapy was superior to standard
herapy, driven by a reduction in bleeding with bivalirudin
onotherapy (56). A common theme among the studies
valuating bivalirudin is the marked reduction in bleeding
bserved when GPI is not routinely administered.
Long-term follow-up from studies comparing enoxaparin
o UFH (57) or tinzaparin (58) in patients with nSTE-ACS
ith relative low rates of early PCI confirmed the superi-
rity of enoxaparin, particularly among patients who pre-
ented with ST-segment deviation (59). Selective inhibitors
f factor Xa such as fondaparinux have the potential to be
afer and easier to use than UFH and low-molecular-weight
eparins because they do not bind avidly to other coagula-
ion factors and have a long half-life permitting once daily
osing (60). In the OASIS-5 (Organization to Assess
trategies for Ischemic Syndromes) trial in 20,078 patients
ith nSTE-ACS, fondaparinux was almost identical to
noxaparin at 9 days for prevention of ischemic complica-
ions, but markedly reduced bleeding (hazard ratio 0.52, p
 0.001) (61). Fondaparinux was associated with a signif-
cant reduction in death at 30 and 180 days. However, an
xcess of guiding-catheter thrombus formation was ob-
erved with fondaparinux.
leeding. Current nSTE-ACS guidelines recommend
ore intensive antithrombotic therapy for patients at high-
st risk for ischemic complications; consequently, these
atients (particularly the elderly and patients with renal
igure 2. Results in ISAR-REACT 2 stratified by baseline troponin. Amon
lacebo) reduced the primary end point by 29%. Meanwhile, there was no
yocardial infarction; RR  risk ratio; uTVR  urgent target vessel revaysfunction) are at a higher risk of bleeding (62). Major pleeding is associated with higher rates of death and
einfarction (62), with worse outcomes among patients with
ore severe bleeding (63), although it is very difficult to
ccurately quantify this relationship due to the presence of
onfounding. Transfusions, which occur more commonly in
atients with greater baseline comorbidities, are themselves
ssociated with a higher risk of adverse events (64). The first
ractical step to minimize the risk of bleeding complications
s to avoid excess dosing of antithrombotic agents, which
ccurred in 42% of patients in the CRUSADE (Can Rapid
isk Stratification of Unstable Angina Patients Suppress
dverse Outcomes With Early Implementation of the
merican College of Cardiology/American Heart Associa-
ion Guidelines) registry (65). Reducing the dose of aspirin
o 75 to 100 mg reduces bleeding without apparent loss of
enefit (66), as does the administration of a proton-pump
nhibitor to patients with prior ulcer bleeding (67). There is
ngoing controversy regarding the risk-benefit of continu-
ng aspirin (68) and clopidogrel (69) until bypass surgery.
lthough off-pump surgery reduces hemorrhage, some sur-
eons are reluctant to forfeit this benefit by operating on
atients who have recently received clopidogrel (69). Cur-
ent practice guidelines recommend continuing aspirin, but
ithholding clopidogrel for 5 to 7 days, before elective
ypass surgery (70).
NTERVENTIONAL CARDIOLOGY IN nSTE-ACS
pdated practice guidelines were released in 2005 by both
he European Society of Cardiology (ESC) (72) and the
merican College of Cardiology (ACC)/American Heart
ssociation (AHA)/Society for Cardiovascular Angiogra-
subgroup with an elevated troponin at baseline, abciximab (compared with
tment effect among patients with a normal baseline troponin (45). MI 
ization.g thehy and Interventions (SCAI) (71,73). New class I recom-
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Year in Review in nSTE-ACS July 18, 2006:386–95endations with evidence level A pertaining to patients
ith nSTE-ACS in the ACC/AHA/SCAI guideline are
ummarized in Table 3. Recommendations for patients with
STE-ACS in the updated ESC PCI guidelines (72) are
imilar, except that a loading dose of 600 mg clopidogrel is
onsidered justifiable (class I, evidence level C) immediately
fter first medical contact if the time to PCI is 2 to 6 h.
lso, the recommended durations of clopidogrel after drug-
luting stents (DES) (6 to 12 months) and after nSTE-
CS (9 to 12 months) are longer (73). Clopidogrel is highly
ost-effective through 1 year after PCI (74), and, when
iven with aspirin for a median of 28 months to patients
ith clinically evident atherothrombosis, reduced the com-
osite of cardiovascular death, myocardial infarction, and
troke by 12% (75).
In the ICTUS (Invasive Versus Conservative Treatment
n Unstable Coronary Syndromes) trial (76) of 1,200 pa-
igure 3. Odds of non-fatal myocardial infarction (MI) from randomizati
able 3. New Class I, Evidence Level A Recommendations in
atients With Non–ST-Segment Acute Coronary Syndrome
ndergoing PCI (71)
. Aspirin 325 mg for a minimum duration depending on the type of
stent utilized:
Bare-metal 1 month
Sirolimus-eluting 3 months
Paclitaxel-eluting 6 months
. Clopidogrel administered as a 300-mg load at least 6 h prior to PCI
followed by 75 mg daily for duration dependent upon the type of
stent:
Bare-metal 1 month
Sirolimus-eluting 3 months
Paclitaxel-eluting 6 months
. Use of drug-eluting stents as an alternative to bare-metal stents in
those whom trial data suggest efficacy
CI  percutaneous coronary intervention.nvasive management of acute coronary syndromes (77). p  0.51 for heterogeneit
ith permission from JAMA (77).ients with positive troponin but no STE who were man-
ged with intensive medical therapy, as recommended by
he nSTE-ACS guidelines, an early invasive strategy did not
educe the primary composite of death, reinfarction, or
ehospitalization for angina through 1 year compared with a
ore selective invasive approach. These findings contrast
ith those of a meta-analysis of 7 similar prior studies that
emonstrated a 25% reduction in new myocardial infarction
ith a routine early invasive strategy (Fig. 3) (77).
While many studies in the past year compared different
ntracoronary stents (71), 2 important findings pertain to
atients with nSTE-ACS. First, DES were associated with
reat reductions in periprocedural CRP and troponin (78).
econd, patients more likely to receive a DES (compared
ith bare-metal stent), were younger, with systolic hyper-
ension, dyslipidemia, no prior coronary artery bypass graft-
ng, and absence of ST-segment deviations or markers of
yonecrosis at presentation (79).
IPID-LOWERING THERAPY
n the past year, ancillary analyses from randomized trials of
ntensive statin therapy and mechanistic studies provided
ew insights into the role of lipid lowering in patients with
CS. The case for intensive statin therapy after nSTE-ACS
as strengthened by a meta-analysis of 6 randomized
ontrolled trials demonstrating that intensive, but not mod-
rate, statin treatment reduces early recurrent ischemic
vents, stroke, CRP, and CD40 ligand (80). A detailed
omparison of 2 trials comparing intensive to moderate
tatin therapy emphasized the importance of intensive
herapy beginning in the early post-ACS phase, and sug-
ested that the early benefit may be associated with a more
end of follow-up in a meta-analysis of 7 trials of routine versus selectiveon to
y across the trials. CI  confidence interval; OR  odds ratio. Reproduced
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July 18, 2006:386–95 Year in Review in nSTE-ACSrofound reduction in CRP achieved with earlier intensive
herapy (Fig. 4) (81). These results have been rapidly
eflected in subsequent changes in the particular statin and
ose prescribed. A trend-over-time analysis in Ontario,
anada, documented a greater than doubling in the use of
torvastatin, 80 mg, within months after publication of the
ROVE IT–TIMI-22 (Pravastatin or Atorvastatin Evalu-
tion and Infection Therapy–Thrombolysis In Myocardial
nfarction-22) and REVERSAL (Reversing Atherosclerosis
ith Aggressive Lipid Lowering) studies (82).
The benefit of atorvastatin, 80 mg, compared with
ravastatin, 40 mg, occurred within 30 days in the PROVE
T–TIMI-22 trial (28% reduction the hazard ratio of death,
yocardial infarction, or rehospitalization for recurrent
CS, p  0.046) consistent with greater early pleiotropic
ffects (83). A number of potential early benefits of statins
hat are independent of LDL have been postulated and
nclude favorable effects on inflammation, endothelial
unction, and the coagulation cascade (84). In a second-
ry analysis from the PROVE IT–TIMI-22 trial, ran-
omization to intensive statin therapy was associated
ith a lower CRP level (p  0.0001) irrespective of the
resence of single or multiple uncontrolled cardiovascular
isk factors (85). Endothelium-dependent flow-mediated
ilation increased between 1 and 4 months after initiating
ither atorvastatin, 80 mg, or pravastatin, 40 mg, in the
RAVER (Intensity of Lipid Lowering with Statins and
igure 4. The high-intensity therapy arm (atorvastatin 80 mg) in the PROV
evel at 1 month (compared with the low-intensity therapy  pravastatin
ith simvastatin 40 mg in the A to Z trial. By 4 months, both intensive treat
ifferent from standard therapy in their respective trials. *p  0.05 (withirachial Artery Vascular Endothelium Reactivity After icute Coronary Syndromes) trial, independent of reduction
n LDL and CRP (86).
Two important observations regarding the safety of
tatins were reported during the past year. An analysis of
5,693 patients from the GRACE (Global Registry of
cute Coronary Events) registry demonstrated that, in
eneral, patients receiving the combination of clopidogrel
nd statin did not have an increase in clinical events, thus
uggesting no adverse interaction exists between these 2
herapies. Indeed, even after adjustment for differences in
aseline variables and bias in treatment allocation, an
nalysis of patients administered aspirin  clopidogrel 
tatin revealed that the group talking all 3 drugs had the
owest mortality (87). In an analysis of patients who
chieved very low LDL concentrations in the PROVE
T–TIMI-22 trial, there was no adverse safety signal while
linical efficacy improved as the LDL was lowered to 40
g/dl (88), thus suggesting that downward adjustment of
he statin dose is not required in patients who achieve very
ow LDL concentrations.
Despite such favorable results with high-intensity statins,
nly 44% of patients randomized to atorvastatin, 80 mg,
ith baseline total cholesterol 240 mg/dl (average LDL
06 mg/dl) achieved the dual goals of LDL 70 mg/dl and
RP 2 mg/l (89). Better control of traditional risk factors
85) and even more potent pharmacologic therapy are
ecessary to achieve these ambitious targets that have been
ssociated with relatively lower rates of death and recurrent
–TIMI-22 trial significantly lowered the median C-reactive protein (CRP)
); however, this was not true of the high-intensity therapy, which began
arms continued to lower C-reactive protein to levels that were significantly
l). Reproduced with permission from Circulation (81).E IT
40 mgschemic complications (90).
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Year in Review in nSTE-ACS July 18, 2006:386–95OMEN AND MINORITIES
oronary artery disease has been traditionally considered a
isease afflicting men, and studies in nSTE-ACS have
redominantly included men. However, 43% of patients
ith ACS discharged from U.S. hospitals in 2003 were
omen (1). In the WISE (Women’s Ischemia Syndrome
valuation) study, gender differences in the onset of disease
nd risk factor distribution, including variability in the
ynergy of traditional risk factors and the presence of novel
isk factors (e.g., hypoestrogenemia, protracted dysmeta-
olic state) were demonstrated (91). These differences may
esult in symptoms that lead to nSTE-ACS despite non-
bstructive epicardial disease. Whereas the traditional ap-
roach to the patient with nSTE-ACS has focused on the
dentification of a critical epicardial stenosis, this is not
ptimal for women, many of whom remain at high risk for
oor outcomes despite the absence of obstructive coronary
rtery disease. Factors such as microvascular dysfunction,
ndothelial dysfunction, increased oxidative stress, elevated
irculating levels of inflammatory markers, and metabolic
erangements appear to be more important mediators of
schemic heart disease in women (92). Thus, in women, an
lternative approach that focuses on the identification of the
ulprit patient, rather than culprit lesion is preferred (93).
Despite a near doubling of awareness of cardiovascular
isease in women over the past decade (94), gender dispar-
ties in the diagnosis and treatment of women with nSTE-
CS persist. Women tend to receive less aggressive acute (95)
nd chronic (96) treatments than men, and suffer an increased
ate of refractory ischemia and rehospitalization (97).
Because a disproportionate percentage of elderly patients
re women, it is not surprising that registries of patients
ith nSTE-ACS in the U.S. (98), Canada (99), and Europe
100) have all found that the elderly are less likely to receive
cute and chronic evidence-based medicines and proce-
ures. Similar studies have demonstrated that blacks are less
ikely than whites to receive evidence-based therapies, par-
icularly invasive procedures (101) and antiplatelet adjuncts
o PCI (102). The racial differences appear to be better
xplained by differences in the quality of care delivered by
ospitals treating minorities (103) than variation in proce-
ure volume (104). Paradoxically, elderly and minority
atients receive fewer of the proven therapies despite being
t higher risk than younger, white patients (99), thus
esulting in poorer clinical outcomes (100,101) and quality
f life (105).
onclusions. Advances in the prior decade, which accel-
rated during the past year, have led to better methods to
stimate the prognosis and treat patients with nSTE-ACS,
esulting in a decline in mortality over time (106). Surpris-
ngly, some simple measures such as obtaining an electro-
ardiogram within 10 min after arrival in the emergency
epartment in patients presenting with chest pain (107) and
ong-term, consistent use of evidence-based secondary pre-
entive therapies in patients post-discharge (108) are sub-ptimal. Because each 10% increase in the guideline adher-
nce rates is associated with a 10% decrease in mortality
109), additional interventions that improve compliance
ith quality measures, such as a computerized physician
rder entry systems (110), should improve outcomes. These
fforts, along with the development of safer and more
ffective therapies, implementation of uniform clinical per-
ormance measures (106), and use of novel strategies (e.g.,
ombination pharmacotherapy [111]), should reduce mor-
idity and mortality in the future for our patients with
STE-ACS.
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